Detalles de la búsqueda
1.
Genome-wide association study meta-analysis of suicide death and suicidal behavior.
Mol Psychiatry;
28(2): 891-900, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36253440
2.
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Int J Neuropsychopharmacol;
25(3): 238-251, 2022 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34791283
3.
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
Compr Psychiatry;
107: 152233, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711781
4.
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
J Clin Psychopharmacol;
39(6): 567-574, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31688450
5.
Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations.
Int J Clin Pract;
72(6): e13089, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29707876
6.
Genome-wide association study of paliperidone efficacy.
Pharmacogenet Genomics;
27(1): 7-18, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27846195
7.
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Int J Neuropsychopharmacol;
19(7)2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902950
8.
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Br J Clin Pharmacol;
82(5): 1364-1370, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27333588
9.
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.
Pharmacogenet Genomics;
25(4): 173-85, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25714000
10.
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.
J Clin Psychopharmacol;
39(2): 180-182, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30811377
11.
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
Eur J Drug Metab Pharmacokinet;
2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38769284
12.
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
Eur J Drug Metab Pharmacokinet;
2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38750386
13.
Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
Psychol Med;
48(12): 2098-2099, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29860947
14.
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
J Clin Psychopharmacol;
33(2): 157-61, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23422378
15.
The impracticality of surgically removing intramuscular long-acting injectable antipsychotic medication.
Am J Emerg Med;
36(3): 522-523, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28818307
16.
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.
Ann Gen Psychiatry;
12(1): 22, 2013 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-23845018
17.
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.
Neuropsychiatr Dis Treat;
19: 531-545, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36915909
18.
Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
Medicine (Baltimore);
102(34): e34623, 2023 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653768
19.
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Neuropsychiatr Dis Treat;
19: 895-906, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37077705
20.
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Int J Neuropsychopharmacol;
15(1): 107-18, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21777507